Bristol-Myers Squibb (BMY)
$54.06
0.37 (0.67%)
BMY Stock Quote Delayed 15 Minutes
Previous Close
$54.42
Market Cap
88.35B
PE Ratio
94.83
EPS
0.57
Volume (Avg. Vol.)
2.25M
Day's Range
53.95 - 54.59
52-Week Range
42.48 - 57.37
Dividend & Yield
1.60 (2.96%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
5 Top Stock Trades for Tuesday: AAPL, GM, SRPT
Apple, General Motors, Delta Air Lines, Sarepta and Bristol-Myers Squibb were our top stock trades to watch for Tuesday. Here's what you need to know.
4 Top Stock Trades for Tuesday: AAPL, DIS, BMY
Apple, Disney, Thor Industries and Bristol-Myers Squibb were our top stock trades from Monday. Here's a look at the charts.
4 Top Stock Trades for Thursday: ROKU, ADBE, BYND
Roku, Adobe Systems, Beyond Meat and Bristol-Myers Squibb are our top stock trades. Read on to see what the charts say.
Amgen to Buy Celgene’s Otezla for $13.4B: Is the Deal Good for Amgen Stock?
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY
Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.
Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
Bristol-Myers Squibb Stock Has Upside — But Mind the Risks
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Risk-Takers Have a Reasonable Shot with BMY Stock
Political pressures regarding drug pricing and Bristol-Myers’ disappointing clinical trails have contributed to a disappointing performance for BMY stock. Still, much of this bearishness could be priced in already.
Fear Around Bristol-Myers Squibb Stock is Starting to Fade
BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
